INTENSITY THERAPEUTICS
Intensity Therapeutics, Inc., a biopharmaceutical company, provides chemotherapy treatments for cancer patients. It engages in the direct intratumoral injection of novel pharmaceutical formulations for cancer administration. Intensity Therapeutics, Inc. was incorporated in 2012 and is based in Norwalk, Connecticut.
INTENSITY THERAPEUTICS
Social Links:
Industry:
Biopharma Biotechnology Therapeutics
Founded:
2012-01-01
Address:
Norwalk, Connecticut, United States
Country:
United States
Website Url:
http://www.intensitytherapeutics.com
Total Employee:
1+
Status:
Active
Contact:
2036641051
Email Addresses:
[email protected]
Total Funding:
11.5 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Google Tag Manager WordPress Google Universal Analytics
Current Employees Featured
Founder
Investors List
Jim Mellon
Jim Mellon investment in Series A - Intensity Therapeutics
SalvaRx Group PLC
SalvaRx Group PLC investment in Series A - Intensity Therapeutics
VCapital
VCapital investment in Series A - Intensity Therapeutics
Batterson Venture Capital
Batterson Venture Capital investment in Series A - Intensity Therapeutics
Declan Doogan
Declan Doogan investment in Series A - Intensity Therapeutics
Official Site Inspections
http://www.intensitytherapeutics.com
- Host name: 157.53.209.35.bc.googleusercontent.com
- IP address: 35.209.53.157
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "Intensity Therapeutics"
Company - Intensity Therapeutics
Our Story Intensity Therapeutics is a clinical-stage biotechnology company whose mission is to help patients live longer, higher quality lives by discovering, developing, and commercializing …See details»
Company Information :: Intensity Therapeutics, Inc. (INTS)
Company Contact Intensity Therapeutics, Inc. 1 Enterprise Drive Suite 430 Shelton, CT 06484-4779 T: 203-221-7381See details»
Intensity Therapeutics - Crunchbase Company Profile & Funding
Contact Email [email protected] Phone Number 2036641051 Intensity Therapeutics, Inc., a biopharmaceutical company, provides chemotherapy treatments for …See details»
Contact - Intensity Therapeutics
Get in Touch For more information on Intensity and the Company’s technology and products in development, please fill out our contact form below. Headquarters: Intensity Therapeutics, Inc.1 Enterprise Drive, Suite …See details»
Intensity Therapeutics, Inc. | LinkedIn
Intensity Therapeutics, Inc. Pharmaceutical Manufacturing Westport, CT 1,014 followers A clinical stage biotechnology company whose mission is to create safer and more efficacious cancer therapies.See details»
Intensity Therapeutics, Inc. (INTS) - Yahoo Finance
See the company profile for Intensity Therapeutics, Inc. (INTS) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives ...See details»
Intensity Therapeutics Inc (INTS-Q) Profile - The Globe and Mail
See the company profile for Intensity Therapeutics Inc (INTS-Q) including business summary, industry/sector information, business summary, corporate governance, key executives.See details»
Intensity Therapeutics - Overview, News & Similar companies
Mar 22, 2024 Wesolowski remains with the organization as Controller & Principal Accounting Officer. Nov 13 2023. ... Phone number: (203) 221-7381 Website: …See details»
Intensity Therapeutics - PitchBook
Intensity Therapeutics General Information Description. Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor …See details»
Intensity Therapeutics - Craft
Aug 16, 2024 Intensity Therapeutics is a clinical-stage biotechnology company that applies an immune-based approach to treat solid tumor cancers. It uses the DfuseRxSM technology …See details»
Intensity Therapeutics, Inc. (INTS)
Nov 18, 2024 Dec 12, 2024 . Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the …See details»
Intensity Therapeutics Provides Business Update Highlighting Key ...
4 days ago Pathological complete response ("pCR") is the primary endpoint. For more information about Intensity, including publications, papers, and posters about its novel …See details»
Board of Directors - Intensity Therapeutics
Prior to her appointment as CEO of PsychoGenics, she was Vice President of Business Development, a position she also held at American Biogenetic Sciences and at AMBI Inc. Dr. …See details»
Intensity Therapeutics Provides Business Update Highlighting Key ...
4 days ago Intensity Therapeutics, Inc. ("Intensity" or the "Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of …See details»
Intensity Therapeutics Reports First Quarter 2024 Financial Results …
May 9, 2024 For more information about the Company, including publications, papers and posters about its novel approach to cancer therapeutics, visit www.intensitytherapeutics.com. …See details»
Senior Management Team - Intensity Therapeutics
James M. Ahlers has served as our Executive Vice President of Corporate Finance since June 2023. Previously, Mr. Ahlers served as our Chief Financial Officer from January 2022 until …See details»
Intensity Therapeutics, Inc. (INTS) - Yahoo Finance Canada
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an …See details»
Intensity Therapeutics Provides Business Update Highlighting Key ...
4 days ago For more information about Intensity, including publications, papers, and posters about its novel approach to cancer therapeutics, visit www.intensitytherapeutics.com.See details»
News & Events - Intensity Therapeutics, Inc.
WESTPORT, Conn., July 10, 2023 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or the "Company") (Nasdaq: INTS), a clinical-stage biotechnology company focused on the discovery …See details»
News & Events - ir.intensitytherapeutics.com
Nov 18, 2024 Disease progression will be determined by the World Health Organization (WHO) criteria. Participants will be prospectively stratified into 1 of 3 histologically defined STS strata: …See details»